Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 303-313

  Hsu, Hsi Hsien ^a,b   Cheng, Li Hao ^c   Ho, Tsung Jung ^c   Kuo, Wei Wen ^c   Lin, Yueh Min ^d,e   Chen, Ming Cheng ^c,f   Lee, Nien Hung ^c   Tsai, Fuu Jen ^c   Tsai, Kun Hsi ^g,h   Huang, Chih Yang ^c,i  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHI MEI MEDICAL CENTER   (Taiwan)

^h NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

ⁱ ASIA UNIVERSITY   (Taiwan)

Author keywords

Akt; Apicidina HA22T; Hepatocellular carcinoma cells; IGF IR PI3K

Indexed keywords

APICIDIN; CYCLIN A; CYCLIN B1; CYCLIN D; CYTOCHROME C; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CARCINOMA CELL; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MICE; PEPTIDES, CYCLIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84893701178     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1041-3     Document Type: Article

References (55)

1. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25(2):212-25.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(10):533-96.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215-9.
4. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347-54.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.
7. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677-85.
8. Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol. 1999;10(9):1011-21.
9. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology. 1996;24(5):1264-8.
10. Demeret C, Vassetzky Y, Mechali M. Chromatin remodelling and DNA replication: from nucleosomes to loop domains. Oncogene. 2001;20(24):3086-93.
11. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168-76.
12. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011;71(12):4138-49.
13. Klampfer L, Huang J, Shirasawa S, Sasazuki T, Augenlicht L. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: the role of signal transducers and activators of transcription 1 and p21. Cancer Res. 2007;67(18):8477-85.
14. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13(6):477-83.
15. Kim YK, Han JW, Woo YN, Chun JK, Yoo JY, Cho EJ, et al. Expression of p21(WAF/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene. 2003;22(38):6023-31.
16. Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology. 2006;130(7):2130-44.
17. Ueda T, Takai N, Nishida M, Nasu K, Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med. 2007;19(2):301-8.
18. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 2000;60(21):6068-74.
19. Kim MS, Son MW, Kim WB, In-Park Y, Moon A. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 2000;157(1):23-30.
20. Weiller M, Weiland T, Dunstl G, Sack U, Kunstle G, Wendel A. Differential immunotoxicity of histone deacetylase inhibitors on malignant and naive hepatocytes. Exp Toxicol Patho. 2011;63(5):511-7.
21. Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, et al. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol. 2009;50(6):1112-21.
22. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Investig. 1995;73(3):311-31.
23. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer. 1992;65(3):311-20.
24. Samani AA, Brodt P. The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am. 2001;10(2):289-312. viii.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
26. Basera R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol. 1996;14(5):150-2.
27. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren 2nd PG, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69(5):1951-7.
28. Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. 2001;7(6):1790-7.
29. Hellawell GO, Ferguson DJ, Brewster SF, Macaulay VM. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int. 2003;91(3):271-7.
30. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005;11(4):1563-71.
31. Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, et al. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther. 2009;8(6):1448-59.
32. Costantini P, Jacotot E, Decaudin Dand Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst. 2000;92(13):1042-53.
33. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. Cancer J Clin. 2008;58(2):71-96.
34. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 1993;7(14):1407-13.
35. Butt AJ, Firth SM, Baxter RC. The IGF axis and programmed cell death. Immunol Cell Biol. 1999;77(3):256-62.
36. Bettaieb A, Dubrez-Daloz L, Launay S, Plenchette S, Rebe C, Cathelin S, et al. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. Curr Med Chem Anticancer Agents. 2003;3(4):307-18.
37. Brenner C, le Bras M, Kroemer G. Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J Clin Immunol. 2003;23(2):73-80.
38. Hersey P, Zhang XD. Overcoming resistance of cancer cells to apoptosis. J Cell Physiol. 2003;196(1):9-18.
39. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004;23(16):2746-56.
40. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther. 2003;2(6):573-80.
41. Kim R, Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer. 2004;101(11):2491-502.
42. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia. 2001;15(7):1022-32.
43. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene. 2002;21(57):8786-803.
44. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305(5684):626-9.
45. Reed JC. Apoptosis mechanisms: implications for cancer drug discovery. Oncology. 2004;18(13 Suppl 10):11-20.
46. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395-419.
47. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590-607.
48. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132-6.
49. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell. 2003;112(4):481-90.
50. Zhivotovsky B, Hanson KP, Orrenius S. Back to the future: the role of cytochrome c in cell death. Cell Death Differ. 1998;5(6):459-60.
51. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305-8.
52. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-45.
53. Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann NY Acad Sci. 2000;926:52-63.
54. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004;23(15):3175-85.
55. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol. 1997;9(1):79-87.